Cautious Optimism For Alzheimer's Mounts Among Industry R&D Leaders

 
• By Jessica Merrill

Some big pharma R&D leaders have signaled enhanced interest in neuroscience R&D – and Alzheimer's more specifically – following FDA's approval of Biogen's Aduhelm based on biomarkers.

Green traffic light
Some R&D leaders are giving Alzheimer's the green light • Source: Alamy

More from Neurological

More from Therapy Areas